Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference

Company Continues to Update its Product Pipeline

News provided by

Dec 09, 2013, 04:05 ET

NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 24^th Annual Oppenheimer Healthcare Conference in New York from December 10^th through 11^th, 2013. Dr. Dave will present a corporate update on Wednesday, December 11, 2013 at 8:20 am Eastern.

Presentation Information:

Date:               Wednesday, December 11, 2013
Time:               8:20 am Eastern
Location:         Crowne Plaza Hotel, New York, NY
Webcast:        http://www.veracast.com/webcasts/opco/healthcare2013/24202378549.cfm

A live webcast of the presentation will be available via the "Investor Relations" event page of the Actinium website, www.actiniumpharmaceuticals.com. A replay of the webcast will also be archived on Actinium's website for 90 days following the presentation.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies. The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contacts:

Media and Investors:
Actinium Pharmaceuticals, Inc.
Corey Sohmer
Phone: (646) 459-4201
E-mail: [email protected]

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: [email protected]

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.